# Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology

> **NIH NIH RF1** · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · 2022 · $3,859,922

## Abstract

ABSTRACT
Mild traumatic brain injury (mTBI, concussion) has emerged as a risk factor for the development of
neurodegenerative disorders such as Alzheimer’s disease (AD) and chronic traumatic encephalopathy, which
are characterized by the aberrant aggregation of tau within neural cells. However, the mechanisms
linking mTBI to AD-related pathology later in life remain unknown.
 Disruption of the sleep-wake cycle (SWD) is a frequent chronic complaint after mTBI and also
accompanies the development of AD. More recent clinical and translational research suggests that SWD
may actually promote the development of Alzheimer’s-related pathology. Our preliminary data show that sleep
disturbance is significantly associated with lower CSF Aβ42 levels (an AD-associated profile) in Veterans with
mTBI >45 years of age. Based on these findings, we propose that post-TBI sleep disruption promotes the
development of AD-related pathology following mTBI. This will be directly tested in Aim 1.
 The glymphatic system is a recently characterized brain-wide network of perivascular spaces that supports
the clearance of both Aβ and tau. Glymphatic function is greatest during sleep and is impaired by TBI. Our
published and preliminary data show that MRI-visible perivascular space burden (MV-PVS), a putative marker
of glymphatic impairment, is increased among Veterans with blast mTBI and that these changes are
associated with AD-related CSF biomarker profiles. In Aim 2, we will use novel MRI-based approaches to test
whether glymphatic impairment predicts the development of AD-related pathology after blast mTBI.
 Sleep-wake behavior is regulated through central noradrenergic (NA) neurotransmission, with locus
coeruleus (LC)-derived norepinephrine (NE) promoting arousal during waking. In our blast mTBI Veterans,
CSF NE was elevated compared to controls and associated with poor sleep. However, the role that changes in
central NA signaling play in promoting AD-related pathology following TBI is unknown. In Aim 3 we will test
whether changes in measures of central NA tone predict the development of AD-related pathology after blast
mTBI.
 Dr. Peskind’s 10-year longitudinal VA cohort will contribute 70 previously- and newly-enrolled Veterans >45
years of age with a history of repetitive blast mTBIs who will undergo assessment of: subjective and objective
sleep; multi-domain clinical behavioral, neurological, and neurocognitive assessment; glymphatic function
measured by MRI, and measurement of CSF/plasma AD/CTE-related biomarkers and NE.
Aim 1. Define the role of sleep disruption in the development of post-TBI AD-related pathology.
Aim 2. Define the role of glymphatic dysfunction in the development of post-TBI AD-related pathology.
Aim 3. Define the role of alterations in central NA tone in the development of post-TBI AD-related
pathology after TBI.

## Key facts

- **NIH application ID:** 10523939
- **Project number:** 1RF1NS128966-01
- **Recipient organization:** SEATTLE INST FOR BIOMEDICAL/CLINICAL RES
- **Principal Investigator:** ELAINE R. PESKIND
- **Activity code:** RF1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $3,859,922
- **Award type:** 1
- **Project period:** 2022-09-20 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10523939

## Citation

> US National Institutes of Health, RePORTER application 10523939, Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology (1RF1NS128966-01). Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/grant/nih/10523939. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*